[go: up one dir, main page]

WO2009111169A3 - Compositions comprising pkc-delta modulators and methods for ocular neuroprotection - Google Patents

Compositions comprising pkc-delta modulators and methods for ocular neuroprotection Download PDF

Info

Publication number
WO2009111169A3
WO2009111169A3 PCT/US2009/034466 US2009034466W WO2009111169A3 WO 2009111169 A3 WO2009111169 A3 WO 2009111169A3 US 2009034466 W US2009034466 W US 2009034466W WO 2009111169 A3 WO2009111169 A3 WO 2009111169A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkc
compositions
delta
methods
delta modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/034466
Other languages
French (fr)
Other versions
WO2009111169A2 (en
Inventor
Keith Wayne Ward
Srini Venkatesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of WO2009111169A2 publication Critical patent/WO2009111169A2/en
Publication of WO2009111169A3 publication Critical patent/WO2009111169A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions for treating or controlling degeneration of at least a component of the human optic nerve system comprise a modulator of protein kinase Gdelta ('PKC-delta'). Such a PKC-delta modulator can be a compound that substantially inhibits, reduces, or interferes with, an activity of a cell signaling cascade involving PKC-delta or activation of PKC-delta. The compositions can also include an anti-inflammatory medicament. Such compositions can be administered to provide neuroprotection to a patient suffering from an ocular disease, such as glaucoma, AMD, DR, or retinitis pigmentosa.
PCT/US2009/034466 2008-02-29 2009-02-19 Compositions comprising pkc-delta modulators and methods for ocular neuroprotection Ceased WO2009111169A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3258408P 2008-02-29 2008-02-29
US61/032,584 2008-02-29

Publications (2)

Publication Number Publication Date
WO2009111169A2 WO2009111169A2 (en) 2009-09-11
WO2009111169A3 true WO2009111169A3 (en) 2010-02-25

Family

ID=40762329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034466 Ceased WO2009111169A2 (en) 2008-02-29 2009-02-19 Compositions comprising pkc-delta modulators and methods for ocular neuroprotection

Country Status (1)

Country Link
WO (1) WO2009111169A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795640B2 (en) 2011-12-22 2014-08-05 Mary Kay Inc. Lip formulation
ITUB20169937A1 (en) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF PIGMENTAL RETINITIS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006516A1 (en) * 2000-07-18 2002-01-24 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
WO2007035782A2 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006516A1 (en) * 2000-07-18 2002-01-24 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
WO2007035782A2 (en) * 2005-09-19 2007-03-29 Kai Pharmaceuticals, Inc. Protein kinase c peptide modulators of angiogenesis
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AZADI S ET AL: "Up-regulation and increased phosphorylation of protein kinase C (PKC) delta, mu and theta in the degenerating rd1 mouse retina", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 31, no. 4, 1 April 2006 (2006-04-01), pages 759 - 773, XP024908201, ISSN: 1044-7431, [retrieved on 20060401] *
GSCHWENDT M ET AL: "Rottlerin, a Novel Protein Kinase Inhibitor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 199, no. 1, 28 February 1994 (1994-02-28), pages 93 - 98, XP024764939, ISSN: 0006-291X, [retrieved on 19940228] *

Also Published As

Publication number Publication date
WO2009111169A2 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2007150018A3 (en) Steroid-containing sustained release intraocular implants and related methods
WO2006071778A3 (en) Treatment of parkinson's disease and related disorders using postpartum derived cells
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
IL188789A0 (en) Formulation and method for administration of ophthalmologically active agents
WO2007047607A3 (en) Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
WO2007109097A3 (en) RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
WO2007038669A3 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2007015739A3 (en) Pea-tempo/pea-bz coatings for controlled delivery of drugs from implantable medical devices
EP1933833B8 (en) Therapy for the treatment of overactive bladder
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2008070132A3 (en) Methods of use of trk receptor modulators
AU2017261303A1 (en) Ophthalmic compositions
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2005009394A3 (en) Drug delivery in the nervous system
WO2009089399A3 (en) Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718261

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718261

Country of ref document: EP

Kind code of ref document: A2